发布求助
文献互助 智能选刊 最新文献

Journal of the advanced practitioner in oncology最新文献

筛选
英文 中文
High Altitude Help: Medical Emergencies in the Air. 高空帮助：空中医疗紧急情况。
Journal of the advanced practitioner in oncology Pub Date : 2024-05-01 DOI: 10.6004/jadpro.2024.15.4.1
Beth Faiman
{"title":"High Altitude Help: Medical Emergencies in the Air.","authors":"Beth Faiman","doi":"10.6004/jadpro.2024.15.4.1","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.4.1","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 4","pages":"233-234"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of the 31-Gene Expression Profile Test to Aid in the Decision of Adjuvant Treatment of Cutaneous Melanoma. 使用 31 基因表达谱检测辅助决定皮肤黑色素瘤的辅助治疗方案
Journal of the advanced practitioner in oncology Pub Date : 2024-05-01 DOI: 10.6004/jadpro.2024.15.4.5
Jillian Hunt
{"title":"Use of the 31-Gene Expression Profile Test to Aid in the Decision of Adjuvant Treatment of Cutaneous Melanoma.","authors":"Jillian Hunt","doi":"10.6004/jadpro.2024.15.4.5","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.4.5","url":null,"abstract":"<p><p>Melanoma is the fifth most common cancer in the United States, with over 7,000 deaths annually. Although most patients diagnosed with early-stage (stage I or II) disease have an excellent prognosis, two out of three patients who die from melanoma were initially diagnosed in early stages. Thus, additional methods to identify which patients are at risk of poor outcomes are needed. DecisionDx-Melanoma is a 31-gene expression profile (31-GEP) molecular risk stratification test that predicts an individual's risk of recurrence or metastasis in patients with cutaneous melanoma (CM). Here, we describe a 61-year-old man who presented with a spot on his upper scalp. A biopsy confirmed malignant melanoma measuring > 3.87 mm, with ulceration and mitotic rate 2 to 3/mm<sup>2</sup>. CT, PET, and MRI scans did not reveal metastasis. Following wide local excision and sentinel lymph node biopsy, he was diagnosed with stage IIB CM. Due to the presence of high-risk features, 31-GEP testing was ordered, which revealed Class 2B (high-risk) CM. Due to the high-risk 31-GEP result, the patient was treated off-label with nivolumab for 1 year and received follow-up surveillance scans every 3 months for 3 years. At his last follow-up in April 2022, scans continued to show no recurrent or metastatic disease. The patient continues dermatologic screening every 6 months. The 31-GEP test provides valuable additional information to help clinicians make personalized, risk-based treatment and surveillance plans for patients with CM.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 4","pages":"277-280"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infusion-Related Reaction Management With Amivantamab for EGFR Exon 20 Insertion Mutation NSCLC: A Practical Guide for Advanced Practitioners. 使用阿米万他单抗治疗表皮生长因子受体外显子 20 插入突变 NSCLC 的输注相关反应管理：高级医师实用指南》。
Journal of the advanced practitioner in oncology Pub Date : 2024-05-01 DOI: 10.6004/jadpro.2024.15.4.2
Lindsay Dougherty, Whitney E Lewis, Meghan O'Neill, Amitabha Bhaumik, Denise D'Andrea, Andy L Johnson
{"title":"Infusion-Related Reaction Management With Amivantamab for <i>EGFR</i> Exon 20 Insertion Mutation NSCLC: A Practical Guide for Advanced Practitioners.","authors":"Lindsay Dougherty, Whitney E Lewis, Meghan O'Neill, Amitabha Bhaumik, Denise D'Andrea, Andy L Johnson","doi":"10.6004/jadpro.2024.15.4.2","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.4.2","url":null,"abstract":"<p><p>Many targeted therapies to treat genetic mutations in non-small cell lung cancer (NSCLC) have been developed. Amivantamab (Rybrevant), a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor, was approved by the US Food and Drug Administration in 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC <i>EGFR</i> exon 20 insertions, whose disease progressed on or after platinum-based chemotherapy. Amivantamab is administered intravenously weekly for 4 weeks, then every 2 weeks starting at Week 5, as 1,050 mg (body weight [BW] < 80 kg) or 1,400 mg (BW ≥ 80 kg), with the first dose split over 2 days. Infusion-related reactions (IRRs) are common with amivantamab and may present as chills, dyspnea, nausea, chest discomfort, and vomiting. To aid in the prevention, diagnosis, and treatment of IRRs, we evaluated infusion duration, IRR timing, and IRR severity in this post hoc analysis of patients who received amivantamab in CHRYSALIS. Infusion duration decreased over time, with a median infusion time at Cycle 1 Day 1 (C1D1) of 4.70 hours (1,050 mg) and 5.08 hours (1,400 mg), decreasing to 2.20 and 2.25 hours, respectively, by C1D22. Of the 273 IRRs, 98% occurred on C1D1 or C1D2, with median onset and time to resolution of 60 minutes. Most IRRs occurred during the infusion, were low grade, and were manageable with intervention strategies or treatment modifications. Advanced practitioners are critical in preventing, diagnosing, and managing IRRs, including educating patients and families, accurately administering infusions, prescribing premedications, and closely monitoring for IRRs.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 4","pages":"245-252"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-2023 Drug Updates: Investigational Therapeutics in the Pipeline. 2022-2023 药物更新：在研治疗药物。
Journal of the advanced practitioner in oncology Pub Date : 2024-04-01 DOI: 10.6004/jadpro.2024.15.3.5
Sandra Cuellar
{"title":"2022-2023 Drug Updates: Investigational Therapeutics in the Pipeline.","authors":"Sandra Cuellar","doi":"10.6004/jadpro.2024.15.3.5","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.3.5","url":null,"abstract":"<p><p>During JADPRO Live 2023, Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Cuellar highlighted new drug classes, novel mechanisms of action, and safety profiles that advanced practitioners should be aware of.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 3","pages":"182-185"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs. 多发性骨髓瘤的个性化治疗：指导治疗方案，满足患者需求。
Journal of the advanced practitioner in oncology Pub Date : 2024-04-01 DOI: 10.6004/jadpro.2024.15.3.10
Beth Finley-Oliver, Rachid Baz
{"title":"Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs.","authors":"Beth Finley-Oliver, Rachid Baz","doi":"10.6004/jadpro.2024.15.3.10","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.3.10","url":null,"abstract":"<p><p>At JADPRO Live 2023 in Orlando, presenters discussed selecting treatment regimens for newly diagnosed and relapsed or refractory multiple myeloma. They also provided insights on comprehensive care centered around patient preferences, treatment goals, side effect mitigation, and supportive care needs of patients with multiple myeloma.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 3","pages":"204-208"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shaping the Future of Oncology at JADPRO Live 2023. 在 JADPRO Live 2023 上塑造肿瘤学的未来。
Journal of the advanced practitioner in oncology Pub Date : 2024-04-01 DOI: 10.6004/jadpro.2024.15.3.1
Beth Faiman
{"title":"Shaping the Future of Oncology at JADPRO Live 2023.","authors":"Beth Faiman","doi":"10.6004/jadpro.2024.15.3.1","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.3.1","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 3","pages":"162-163"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing the Care of Patients With Colorectal Cancer in Clinical Practice. 在临床实践中优化对结直肠癌患者的护理。
Journal of the advanced practitioner in oncology Pub Date : 2024-04-01 DOI: 10.6004/jadpro.2024.15.3.8
Mary B Morgan, Tammy Triglianos
{"title":"Optimizing the Care of Patients With Colorectal Cancer in Clinical Practice.","authors":"Mary B Morgan, Tammy Triglianos","doi":"10.6004/jadpro.2024.15.3.8","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.3.8","url":null,"abstract":"<p><p>At JADPRO Live 2023, presenters emphasized the importance of increasing colorectal cancer screening in high-risk groups, reviewed guidelines in the adjuvant and metastatic setting, and outlined clinical and molecular profiles to consider when discussing and determining treatment options with patients.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 3","pages":"196-199"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-2023 Drug Updates in Solid Tumors. 2022-2023 年实体瘤药物更新。
Journal of the advanced practitioner in oncology Pub Date : 2024-04-01 DOI: 10.6004/jadpro.2024.15.3.3
Lisa M Holle
{"title":"2022-2023 Drug Updates in Solid Tumors.","authors":"Lisa M Holle","doi":"10.6004/jadpro.2024.15.3.3","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.3.3","url":null,"abstract":"<p><p>At JADPRO Live 2023 in Orlando, Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP, briefed advanced practitioners on key US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Holle described indications, mechanisms of action, and monitoring and management of side effects of new therapies in solid malignancies.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 3","pages":"170-176"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-2023 Drug Updates in Hematologic Malignancies. 2022-2023 年血液恶性肿瘤药物更新。
Journal of the advanced practitioner in oncology Pub Date : 2024-04-01 DOI: 10.6004/jadpro.2024.15.3.4
Rebecca L Rezac
{"title":"2022-2023 Drug Updates in Hematologic Malignancies.","authors":"Rebecca L Rezac","doi":"10.6004/jadpro.2024.15.3.4","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.3.4","url":null,"abstract":"<p><p>At JADPRO Live 2023 in Orlando, Rebecca L. Rezac, PharmD, BCOP, summarized key information on US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Rezac described indications, mechanisms of action, and monitoring and management of side effects of new therapies for hematologic malignancies.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 3","pages":"177-181"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving Prostate Cancer Patient Care in the Clinical Setting. 改善前列腺癌患者的临床护理。
Journal of the advanced practitioner in oncology Pub Date : 2024-04-01 DOI: 10.6004/jadpro.2024.15.3.9
Jessica Deinert, Leah K Shaw
{"title":"Improving Prostate Cancer Patient Care in the Clinical Setting.","authors":"Jessica Deinert, Leah K Shaw","doi":"10.6004/jadpro.2024.15.3.9","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.3.9","url":null,"abstract":"<p><p>At JADPRO Live 2023 in Orlando, presenters provided an overview of best practices in the diagnosis, classification, and management of patients with localized and metastatic prostate cancer. They covered selecting appropriate therapies based on patient clinical presentation and treatment goals, as well as managing side effects and interventions for modifiable health risks in patients with prostate cancer.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 3","pages":"200-203"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信